

2026-2027 SEASONAL RESPIRATORY VIRUS IMMUNIZATION CAMPAIGN

	Immunizing product selection		
Target groups :	Influenza ¹	COVID-19	RSV and RSV mAb
Children (0-17 years)	From 6 months of age: Fluzone /Fluviral 0,5ml IM	N/A	Nirsevimab Newborns born during the RSV season (September 30, 2026, or later) and infants under 8 months of age (born since February 1, 2026) who have never received an RSV monoclonal antibody: 0,5ml (under 5kg) or 1,0ml IM (5kg or more) Infants under 19 months of age (born on or after March 1, 2025) who have one of the conditions associated with RSV vulnerability²: 2 injections of 1,0 ml IM
Adults (18 years and older)	Fluzone /Fluviral 0,5ml IM or Age 75 years and older: Flud 0,5ml IM if available	Spikevax 0,5ml IM or Comirnaty 0,3ml IM	Community-dwelling adults aged 75 years and older: mRESVIA 0,5ml IM
Pregnant women			
Healthcare workers			
Individuals ≥ 6 months of age with chronic medical condition(s)³, on dialysis and/or immunocompromised	Fluzone /Fluviral 0,5ml IM or Adults aged 75 years and older with chronic diseases: Flud 0,5ml IM if available	Spikevax 6months-11 years: 0,25ml IM (<i>multidose vial only</i>) 12 years and older: 0,5ml IM or Comirnaty 12 years and older: 0,3ml IM	See the Nirsevimab section above for RSV immunization indications in infants under 19 months of age. Individuals aged 18 years and older who have undergone a hematopoietic stem cell transplant (HSCT) within the previous two years or a lung transplant: Arexvy 0,5ml IM
Long-term care facilities (CHSLDs in Kuujjuaq and Puvirnituk)	Fluzone /Fluviral 0,5ml IM or Adults aged 65 years and older: Flud 0,5ml IM	Spikevax 0,5ml IM or Comirnaty 0,3ml IM	Adults aged 60 years and older: Arexvy 0,5ml IM (if never previously vaccinated against RSV)
Private seniors' residence	Fluzone /Fluviral 0,5ml IM or Adults aged 75 years and older: Flud 0,5ml IM if available	Spikevax 0,5ml IM or Comirnaty 0,3ml IM	Adults aged 75 years and older: Arexvy 0,5ml IM (if never previously vaccinated against RSV)

¹ Influenza vaccination should be offered to individuals living in the same household as people belonging to a high-risk group, as well as to their caregivers, including household contacts of children younger than 6 months.

² Refer to the MSSS page [Ac-VRS : anticorps monoclonal contre le virus respiratoire syncytial \(VRS\) - Immunoglobulines et anticorps monoclonaux - Professionnels de la santé - MSSS](#) for additional details on eligible vulnerability conditions.

³ Refer to the table [Fiche indicative concernant la vaccination contre la grippe, contre la COVID-19 et contre le virus respiratoire syncytial \(VRS\)](#) or to the PIQ for more details on eligible chronic diseases.